BU-NOT-SET

CONTACT US
A CDMO’s insight into the pharma M&A landscape
  • Industry trends
Eyes
Insight
Recipharm’s continuous global support throughout the COVID-19 pandemic
  • Industry trends
Eyes
Insight
Is outsourcing the most viable pathway for innovators?
  • Manufacturing
Meeting
Insight
Developing a generic prolonged-release isosorbide-5-mononitrate tablet
  • Drug product
Two lab workers
Case study
Recipharm Wins two 2020 CMO Leadership Awards
  • Industry trends
Eyes
Insight
Recipharm’s global teams support and engage with their local communities in the fight against COVID-19
  • Corporate
Eyes
Insight
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
  • Manufacturing
Eyes
Insight
Recipharm 25 years
  • Corporate
24 years
Brochure
API product list
  • Drug substance
white pills
Fact sheet
Insight
  • Manufacturing
Serialisation | the past, the present and the future
Insight
  • Industry trends
Mergers and acquisitions | meeting customer demand
Insight
  • Manufacturing
DSCSA deadline | our views
Insight
  • Manufacturing
Serialisation: an investment not an expense
Insight
  • Drug product
Solving the solubility setback
Insight
  • Industry trends
Pharmaceutical mega-trends: the rise of consolidation
Insight
  • Manufacturing
What the new Drug Supply Chain Security Act (DSCSA) deadline means for the industry
Insight
  • Drug substance
Automating excipient selection using high-throughput screening
Insight
  • Manufacturing
Serialisation: is the industry ready?